Aprea: Funding, Investors & Team (Sep 2026)
Aprea is a biotechnology company that specializes in finding and creating new anti-cancer drugs that activate the tumor suppressor protein p53. Their main drug in development, APR-246, is a pioneering small molecule treatment currently undergoing clinical trials. Founded in 2003 in Stockholms Lan, Sweden, Aprea Therapeutics was created by Klas Wiman and Galina Selivanova.
Aprea has raised $16.0M across 1 funding round on record, the most recent an undisclosed round of $16.0M announced in Mar 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aprea Company Profile and Key Stats
Latest funding round on record: Mar 2024.
Aprea Funding Rounds
Aprea Founders and Leadership Team
No contact details are on record for this team yet.
Aprea Funding Compared to Other Biotechnology Startups
Aprea's latest round of $16.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aprea in Biotechnology and Stockholm
Companies Similar to Aprea
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic…
Emulsi Biotech is a biotechnology company that develops lipid technology to deliver biologic drugs orally.
Our vision is to develop and bring to the market safe and effective treatments for women specific diseases…
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer…
Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for…
Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for…
Moleculent is dedicated to creating tech-based products that utilize fresh knowledge about the molecular…
Bio-Works was established in 2006 and specializes in creating, producing, and distributing cutting-edge…
Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in…
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic…
ArgusEye is a biotech firm that offers sensor solutions for instant identification of biological systems and…
Aprea Funding FAQs
What does Aprea do?
Aprea is a biotechnology company that specializes in finding and creating new anti-cancer drugs that activate the tumor suppressor protein p53. Their main drug in development, APR-246, is a pioneering small molecule treatment currently undergoing clinical trials. Founded in 2003 in Stockholms Lan, Sweden, Aprea Therapeutics was created by Klas Wiman and Galina Selivanova.
How much funding has Aprea raised?
Aprea has raised $16.0M across 1 round on record. The most recent is an undisclosed round of $16.0M announced in Mar 2024.
When did Aprea last raise funding?
Aprea's most recent funding round on record is an undisclosed round of $16.0M, announced in Mar 2024.
Who founded Aprea?
FundedIQ lists Emily Aprea (Founder) at Aprea.
Where is Aprea headquartered?
Aprea is based in Stockholm, Stockholms Lan, Sweden.
How many employees does Aprea have?
Aprea is in the 1-10 employee band.
How does Aprea's funding compare to other Biotechnology startups?
Aprea's latest round of $16.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Aprea Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aprea is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.